Although the majority of such studies suggested a significant association between tumor PD-L1 expression and anti-PD-1/PD-L1 MoAbs activity [20, 24, 27], the two largest phase III randomized CheckMate 017 and 057 trials have shown opposite results. The gene discussed is CD274; the disease is neoplasm.